Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
ARGATROBAN IN SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, platelet activation, and clot formation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Initial dose: 2 mcg/kg/min IV continuous infusion; maintenance: titrate to aPTT 1.5-3 times baseline, not to exceed 10 mcg/kg/min.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life: 39–51 minutes (mean ~45 min) following intravenous infusion. In hepatic impairment, half-life is prolonged up to 3-fold. Short half-life allows rapid offset of anticoagulation if needed.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily hepatic (biliary/fecal); approximately 65% excreted in feces and 22% in urine (unchanged drug minimal). Renal elimination accounts for 16% as unchanged drug. Dosage adjustment required for hepatic impairment; not significantly affected by renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte